Telehealth startups including Ro and Nurx are spending millions to promote themselves as easy dispensers of medicines. Some ...

Three publicly traded telehealth companies spent a total of more than $1.4 billion on advertising, sales, and marketing in 2023, according to financial reports filed with the Securities and ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to Business Insider. The company, which has faced financial difficulties, ...

The market is set to grow from USD 106.0 billion in 2023 to USD 912.0 billion by 2033, at a CAGR of 24%. Increasing demand ...

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

23andMe (ME) has been quietly exploring a possible sale of its telehealth business, Lemonaid, according to Business Insider. Published first on TheFly – the ultimate source for real-time ...

LifeMD generates solid revenue growth but trades at a 1.08x sales multiple. Find out why LFMD stock’s preferreds offer ...

Me still merchandises its ancestry, health analysis, and the Total Health annual package on a scale from $99 to $999 annually. Lemonaid entered the hot GLP-1 prescribing and support business in 2024, ...

23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million.

Two executives at a telehealth start-up have been arrested and are facing allegations of fraud involving the distribution of medicines for attention-deficit hyperactivity disorder (ADHD).